Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection

NCT02074514 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02074514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02074514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2014
Completion date
November 30, 2015
Enrollment
117 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hcv infection